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According to the authors, the guidelines contains the 
most justified principles of diagnostic and therapeutic 
procedures. They should, however, be interpreted in the 
context of the individual clinical situation. Recommenda-
tions do not always correspond to the current refund rules 
in force in Poland. In case of doubt, you should be sure of 
the current refund possibilities of each procedure.
Introduction 
Pain is one of the most common symptoms oc-
curring in patients with cancer. Each patient has an 
inalienable right to receive the most effective analgesic 
management, and each physician and each nurse has an 
obligation to provide an appropriate analgesic therapy 
in order to assure the best possible quality of life to the 
patient and his/her caregivers [1]. 
The International Association Study of Pain (IASP) 
defines pain as: “An unpleasant sensory and emotional 
experience associated with actual or potential tissue 
damage, or described in terms of such damage”. Pain 
may be defined by its duration (acute or chronic), 
pathomechanism (nociceptive, neuropathic or mixed), 
and location (localised or generalised). Untreated or 
inefficaciously treated pain may negatively influence 
the functioning of the organism. Pain is a risk factor 
of occurrence or exacerbation of shock syndromes, 
it compromise the immunity of the human organism 
and decreases patients' quality of life. Pain may also 
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impede or even preclude efficient anticancer therapy 
and lead to a significant increase of cost of the thera-
peutic management. Inefficaciously or untreated pain 
may cause emotional and psychotic disorders as well as 
depression [2]. Pain should be considered and treated 
in the context of each particular clinical situation. The 
general patient’s status, other symptoms and comorbidi-
ties, and the administered anticancer treatment as well 
as the nonmedical aspects (psychological, social, and 
spiritual problems of patients and of their caregivers) 
should also be considered.
The prevalence of pain is estimated to be about 
40–50% of patients during oncological therapy and 
about 60–70% of patients with advanced cancer [3].
The current standards of analgesic management of 
cancer patients are presented in this section.
Clinical assessment of pain
The assessment of pain is a subjective phenomenon 
that results from the individual sensitivity of a patient 
to pain stimuli, and from the multidimensional influ-
ence of pain on the physical, psychical, social, and 
spiritual sphere. Patients’ psychical condition and 
their personality traits influence the perception of 
pain. The absence of objective pain assessment tools 
poses another practical problem, and consequently the 
clinical evaluation of pain is still based on the patient’s 
subjective relation. When self-evaluation is not feasible 
the pain must be evaluated by caregivers and by health 
professionals. 
A visual analogue scale (VAS) is a simple tool that 
enables the individual evaluation of pain intensity. In 
VAS the patient indicates a point representing the in-
tensity of the experienced pain on a 10-cm continuous 
line (from “no pain” to “the most severe pain inten-
sity”). The numerical rating scale (NRS) is a standard 
tool used to assess the intensity of pain in daily clinical 
practice. In the NRS a patient defines the intensity of 
pain by choosing an adequate number from 0 (no pain) 
to 10 (the most severe pain). A Likert descriptive scale is 
also sometimes used to define pain intensity (“no pain” 
— “weak pain” — “moderate pain” — “severe pain” 
— “very severe pain”). In the case of children, persons 
who do not speak the language, illiterates, and patients 
with cognitive disorders and with dyslexia, pictorial 
scales are used (e.g. facial expression). The evaluation 
of the intensity of pain should be done before the onset 
of therapy, and regular monitoring of the intensity of 
pain should be continued during the treatment. Some 
tools, adapted to the situation in Poland, provide more 
detailed evaluation of pain: the Memorial Pain As-
sessment Card (MPAC) and the Brief Pain Inventory 
— Short Form. The fist tool, MPAC, consists of:
 — three numeric scales in which the patient evaluates 
the intensity of pain, pain relief, and general mood as 
well as the intensity of pain, with use of a verbal scale;
 — a section filled out by a physician or a nurse, which 
includes the pathomechanism, localisation, and type 
of pain (background and a breakthrough pain) and 
the administered therapy.
The BPI-SF formulary includes numeric scales 
evaluating the intensity of the pain and pain relief in the 
past 24 hours as well as the influence of pain, in the same 
period of time, on the daily activities of the patients. 
In patients with a neuropathic component of pain, 
some different sensory symptoms may be present, 
which may coexist in different combinations. That 
is why a clinical examination should include touch, 
prick, pressure, low and high temperature, vibration, 
and temporal summation. Several scales (screening 
tools) based on the verbal description of pain have 
been developed in the past few years. These scales 
may or may not include some elements of the clinical 
examination, and they significantly improve the recog-
nition of neuropathic pain as well as the implementa-
tion of adequate therapy. The Leeds Assessment of 
Neuropathic Symptoms and Signs Scale (LANSS), for 
example, includes five questions concerning pain and 
two elements of clinical examination; the specificity of 
this scale reaches 85% and sensitivity 80% — when the 
number of points exceeds 12/24 it means that the pain 
has mostly neuropathic character. 
Another scale, the Douleur Neuropathique 4 Ques-
tion scale (DN4), includes seven questions concerning 
the symptoms and three elements of clinical examina-
tion. The specificity of this scale reaches 83% and sensi-
tivity 90%. If the number of points exceeds 4/10 it means 
that the pain has mostly neuropathic character [4].
Pathophysiology of pain
The pathophysiology of pain includes two main 
mechanisms. The first is related to the mechanical 
and/or chemical irritation of the nociceptors and 
causes nociceptive pain (somatic, visceral). The second 
mechanism — independent from the activation of the 
nociceptors — is caused by the injury of the soma-
tosensory nervous system and causes neuropathic pain. 
Neuropathic pain is characterised by the hyperalgesia 
phenomena (an increased sensitivity to pain stimuli) 
and allodynia (pain induced by stimuli that normally 
do not cause any pain). The characteristics of the neu-
ropathic pain that are often reported by the patients 
include the sensation of burning, pins and needles, or 
popping with frequent coexistence of sensation dis-
orders or a sensation similar to an electric shock-like 
sensations. It should be stressed that the neuropathic 
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pain is more difficult to manage than the nociceptor 
pain in which the efficacy of the non-opioid analgesics 
and of the opioids is significantly higher. It is worth 
mentioning that that somatic bone pain also presents 
some features of neuropathic pain and is qualified as 
a pain with a neuropathic component. 
If possible, therapy of the chronic pain should be 
directed to the underlying pain pathophysiology, which 
may result in permanent relief and prevent other com-
plications. 
The pain experienced by patients, depending on the 
time of its occurrence, may be divided into background 
pain and breakthrough pain, also known as episodic 
pain [5]. Background pain persists for over 12 hours in 
a day, while a breakthrough pain is defined as an attack 
of a severe and usually transient pain that increases 
rapidly and appears despite efficient therapy of the 
background pain. The time to the maximal intensity of 
the breakthrough pain ususally equals several minutes, 
and the median time of its duration is about 30 min-
utes. However, a breakthrough pain episode may last 
from several dozen seconds to several hours. Recent 
publications have shown that episodic pain may also be 
diagnosed in patients with uncontrolled background 
pain, when opioids are not administered, and in the 
absence of background pain. A breakthrough pain may 
occur without any defined cause (spontaneous or idi-
opathic pain), but it may also be triggered by a particular 
factor (incidental pain). End-of-dose pain, which occurs 
before the administration of the next dose of a regularly 
used analgesic and which requires modification of the 
therapy of the background pain, is not classified as 
breakthrough pain [6]. 
Incidental pain may be divided into involuntary: in-
dependent of the patient’s will, or voluntary: triggered by 
predictable and voluntary patient activity or nursing, di-
agnostic and therapeutic procedures (procedural pain). 
The strategy of treatment of spontaneous and incidental 
involuntary pain consists of using rapid-onset analgesic 
drugs at the moment of pain occurrence, in order to 
assure the most effective analgesia in a minimal period 
of time. Products containing fentanyl, which have rapid 
onset of action and are absorbed through the mucosa 
(intranasal, buccal, and sublingual routes), are usually 
used for this purpose. In the case of occurrence of pain 
induced by predicted and voluntary activity of patients 
or by nursing, diagnostic and therapeutic procedures 
(procedural pain) it should be prevented effectively by 
pre-emptive use of an appropriate dose of analgesic, 
which will efficiently prevent or significantly decrease 
the intensity of the incidental pain. For this purpose, 
typically immediate-release formulations of opioids are 
administered by an oral or parenteral routes (subcuta-
neously — usually at home, intravenously — usually at 
in-patient units) [7].      
The basic rules of analgesic 
management of cancer patients 
Pharmacological treatment 
In the analgesic management of cancer patients both 
pharmacotherapy and nonpharmacological methods 
are used (II, A).
In the therapy of background pain (continuous pain) 
the pharmacotherapy should be conducted continuously 
in order to maintain a stable, therapeutic concentra-
tion of the drugs in the blood. The analgesics should 
be administered at regular intervals, and the route of 
administration should be comfortable for the patient. 
However, the oral route of drug administration should 
be preferred whenever possible. If the patient prefers 
another route of administration or when oral therapy 
is not feasible or complicated by some adverse events 
that are difficult to manage, an alternative route of 
administration of the analgesic drug should be applied. 
The efficacy should be monitored and adverse effects 
of the treatment should be prevented and managed. 
The use of analgesic drugs is based on the analgesic lad-
der developed by the World Health Organisation (WHO), 
which divides analgesic drugs into three groups [8]:
 — step I — non-opioid analgesics (NSAIDs, non-ste - 
roid anti-inflammatory drugs) or paracetamol or 
metamizole; 
 — step II — so-called “weak” opioids (tramadol, co-
deine, and dihydrocodeine);
 — step III — so-called “strong” opioids (morphine, oxy-
codone, oxycodone/naloxone, fentanyl, buprenor-
phine, tapentadol, methadone, hydromorphone).
Treatment is based on the individual choice of 
analgesic drug that is adequate to the intensity of the 
patient’s pain. The therapy should be started from step 
I non-opioid analgesics administered alone when pain 
intensity is rated as 1–3 NRS. In patients with pain of 
moderate intensity (NRS 4–6), the therapy should be 
started “weak” opioids of step II or low doses of “strong” 
(step III) opioids. During the administration of “strong” 
opioids no ceiling effect occurs, which is observed dur-
ing treatment with non-opioid analgesics and “weak” 
opioids. This allows to expect a better analgesic effect 
after dose escalation in the majority of patients. When 
WHO pain ladder step II and III opioids are used, a con-
comitant administration of non-opioid analgesics may be 
considered (a different mechanism of analgesic action). 
On the other hand, it is not recommended to combine 
step II and III opioids. The indication for use of the 
adjuvant drugs may occur at every step of the therapy. 
The adjuvant drugs includes the group of co-analgesics 
(adjuvant analgesics), which increase the analgesic effect 
of opioids in some types of pain (mostly in neuropathic 
and bone pain as well as in visceral colicky pain) and of 
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the drugs used in the prevention of opioid-induced side 
effects (laxatives and antiemetics).    
The basic rules of the pharmacotherapy of pain in 
cancer patients includes:
 — administration of analgesics by an oral or transder-
mal route if possible;
 — regular administration of analgesic drugs in the 
management of background pain and on an ad hoc 
basis in episodes of pain exacerbation;
 — the choice of analgesics should depend on pain 
intensity evaluated by the patient;
 — the drug dose should be individually adjusted in 
order to provide efficient analgesia and acceptable 
adverse effects;
 — monitoring should be carried out of the analgesic 
efficacy, of the side effects, and of patients’ and 
caregivers’ quality of life. 
Non-opioid analgesics 
Non-opioid analgesics are used alone in mild pain 
intensity (NRS 1–3) and together with opioids in moder-
ate (NRS 4–6) and severe (NRS 7–10) pain intensity.
Non-steroid anti-inflammatory drugs (NSAIDs) 
block the synthesis of prostaglandins through the in-
hibition of the cyclooxygenase (COX) activity and, to 
a lesser degree, through the expression of the induced 
isoform of the nitric oxide synthase. Because the ma-
jority of NSAIDs are weak acids and may damage the 
gastric and duodenal mucosa, concomitant use of proton 
pump inhibitors is recommended in the risk group pa-
tients. The negative effect of NSAIDs on the liver may be 
manifested by the usually asymptomatic elevation of the 
aminotransferases. Nimesulide may demonstrate some 
more intensified hepatotoxicity. The negative impact of 
the NSAIDs on the kidneys may lead to the occurrence 
of peripheral oedemas and in some cases to acute renal 
insufficiency. In some and up to a dozen or so per cent 
of patients treated with the acetylsalicylic acid or with 
NSAIDs, bronchial asthma attacks may occur. Acetyl-
salicylic acid is an irreversible inhibitor of thromboxane 
synthesis. There is a diversified risk of vascular complica-
tions associated with the use of NSAIDs. Naproxen has 
the lower risk of this type of complication; however, the 
drug has a long plasma half-life. The choice of drug from 
the NSAID group should be based on the individual 
evaluation of patients regarding the estimated analgesic 
efficacy and the toxicity profile of each particular drug. 
In elderly patients who are chronically treated with 
NSAIDs a special precaution should be taken due to 
the increased risk of intensification of heart and renal 
failure. The parenteral or per rectum administration of 
NSAIDs does not improve the quality of the analgesia 
and does not reduce the prevalence of the side effects 
compared to the oral route. Concomitant use of two 
NSAIDs is not recommended because it does not im-
prove the analgesic efficacy but significantly increases 
the risk of damage of the gastrointestinal tract mucosa 
and of any other side effects. NSAIDs show important 
efficacy in the therapy of bone pain. 
Paracetamol shows analgesic and antipyretic ac-
tivity but has no peripheral anti-inflammatory effect. 
At therapeutic doses it does not produce side effects 
typical for NSAIDs involving the gastrointestinal tract 
and kidneys. The clinical effect of paracetamol admin-
istration is observed in 15–30 minutes depending on 
the pharmaceutical form of the drug. If paracetamol is 
used at the recommended doses (the maximal dose of 
4 g per day, and in elderly patients 2 g per day), usually 
no severe adverse effects are observed except for some 
allergic reactions. In long-term treatment and when 
higher doses are used adverse events may occur. The 
liver is often involved. Paracetamol is contraindicated 
in patients with liver failure. In cases when tretment 
with paracetamol is long-lasting we should be especially 
cautious regarding patients with cachexia, who abuse 
alcohol, and who receive barbiturates. Paracetamol 
does not induce bronchospasm in asthma patients. The 
combination of NSAIDs and paracetamol produces 
a synergic analgesic and antipyretic effect [9].
Metamizol is a non-opioid analgesic that has no 
anti-inflammatory effect. The mechanism of its analgesic 
activity is mostly based on the inhibition of COX-2 and 
COX-3 in the central nervous system (CNS) and to 
a lesser extent on the inhibition of COX-1 and probably 
also on the activation of opioid system. The drug has 
a spasmolytic effect, which is important in the therapy of 
the acute colicky pain. The maximal daily dose of meta-
mizole is 5 g. In cancer patients the drug is mostly used 
to treat breakthrough pain and colicky pain. Metamizole 
should not be given continuously for a period longer than 
seven days due to the increased risk of its side effects, 
especially concerning the haema topoietic system. 
Opioid analgesics 
Opioids play a key role in the therapy of the 
moderate to severe pain intensity in cancer patients 
through their influence on the three types of opioid 
receptors: µ, d, and k, which are contemporarily de-
fined as MOR, KOR, and DOR, respectively. The 
opioid receptors are localised in many structures of 
the central and peripheral nervous system. The effects 
of opioid activity depends on many factors, including: 
their affinity to the opioid receptors, their influence 
on the serotoninergic, adrenergic system as well as 
on the N-methyl-D-aspartate (NMDA) receptors, 
on their physicochemical properties, and on their 
pharmacokinetic characteristics. In the treatment of 
breakthrough pain the dose of short-acting opioid 
(immediate-release formulations) administered by an 
oral route usually equals approximately 10–20% of the 
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total daily dose of the regularly administered opioid. 
In the case of use of rapid-onset fentanyl products 
administered transmucosally, the rule of titration from 
the lowest dose of a particular product should be always 
applied. This rule concerns also the switch from one 
fentanyl product to another one (including products 
with the same route of administration, e.g. intranasally) 
and also any important changes in the therapy of the 
background pain (any important change of the basic 
opioid dose or rotation of opioids).   
WHO analgesic ladder step II opioids (“weak” opioids)
Opioids of step II WHO analgesic ladder are 
typically used in patients with moderate pain intensity 
(NRS 4–6) [10]. Exceeding the recommended maximal 
doses of “weak” opioids usually does not provide any 
additional analgesic effect, whereas it may intensify 
the side effects (ceilling effect of analgesia). Tramadol, 
codeine, and dihydrocodeine are accessible in Poland 
(Table 1). 
Tramadol is the most frequently used WHO anal-
gesic ladder step II opioid, which has a several-times 
weaker analgesic effect compared to morphine (II, A). 
Tramadol shows a double mechanism of analgesic action: 
despite the influence on the opioid receptors (mostly µ) 
in the CNS, it activates a descendent antinociceptive 
system through the inhibition of noradrenaline and 
serotonin reuptake. Tramadol is metabolised in the 
liver by the cytochrome P-450 enzyme and then ex-
creted 90% (after oral administration) by the kidneys 
and 10% in stools. The analgesic effect of tramadol 
depends on the activity of the CYP2D6 enzyme, which 
catalyses the transformation of the basic substance into 
the O-desmethyltramadol (M1), which shows a signifi-
cant analgesic effect through the activation of opioid µ 
receptors. Nausea, vomiting, and excessive sweating, 
especially at the beginning of the therapy, are the most 
commonly observed side effects. The advantage of 
tramadol is its weak negative influence on propulsive 
GI motiltity and lower constipating effect compared 
to other opioids. Tramadol is available in different 
formulations, also as controlled-release tablets. The 
tablets, capsules and drops (40 drops = 100 mg) are 
administered by an oral route, and ampoules may 
be administered subcutaneously, intravenously, and 
less frequently intramuscularly. Tramadol should be 
administered at daily doses of up to 400 mg, every 
4–6 h in immediate-release formulations or every 12 h 
in controlled-release products. In the management of 
breakthrough pain occurring during the basic analgesic 
therapy with tramadol, immediate-release tramadol 
formulations are used. Tramadol is also available in 
combination with paracetamol, which accelerates the 
start of the analgesic effect of this drug and provides 
a synergistic analgesic effect. 
Due to the prolonged plasma half-life of tramadol 
and of its active metabolite, in the case of renal failure it 
is recommended to reduce the drug dose and to prolong 
the intervals between the consecutive doses or to switch 
to another opioid. Prolongation of the time intervals 
between the consecutive doses of the drug and reduction 
of the drug dose are also recommended in patients with 
impairment of liver function. In patients with history 
of epilepsy, tramadol is not recommended due to an 
increased risk of occurrence of convulsions. Due to the 
increase of the concentration of porphyrins, tramadol 
increases the risk of attacks in patients with porphyria. 
Tramadol should not be administered together with 
inhibitors of the reuptake of serotonin and with tricyclic 
antidepressants because it may induce symptoms of the 
serotonin syndrome. The combination of tramadol with 
carbamazepine should also be avoided because it impairs 
its analgesic effect.
Codeine is a µ opioid receptor agonist the analgesic 
effect of which is about ten-fold weaker than morphine 
(I, A). Codeine is a prodrug; it shows an analgesic 
effect dependant on its transformation to morphine, 
which is catalysed by CYP2D6 enzyme and from other 
metabolites (mostly codeine-6-glucuronide). Due to 
its strong antitussive activity, it is considered a drug of 
choice in patients with moderate-intensity pain, who 
concomitantly have a cough. Constipation is a frequent 
side effect of codeine. Codeine is administered only 
orally as immediate-release tablets or as a solution. The 
analgesic effect starts after 15–30 minutes and lasts for 
about 4–6 hours (T1/2 3–4 hours). The maximal daily dose 
is 240 mg. Codeine is also available in combination with 
paracetamol and caffeine, with ASA, and with ibuprofen.
Dihydrocodeine (DHC) is a derivative of codeine. 
The potency ratio of DHC compared to oral doses of 
morphine is 5:1. The drug is mostly metabolised to 
DHC-6-glucuronide and to dihydromorphine. Its side 
effects are usually weaker compared to codeine. In 
contrast to codeine and tramadol the analgesic effects of 
DHC do not depend on the activity of the CYP2D6 en-
zyme. DHC is only available as controlled released tab-
lets, which should be used every 12 hours. The maximal 
daily dose of DHC is 240 mg. DHC is recommended in 
patients with moderate intensity pain frequently with 
cough and dyspnoea.
A common propriety of the metabolism of codeine 
and tramadol is the dependence of the analgesic effect 
and of the side ef fects on the genetically conditioned 
activity of CYP2D6 enzyme as well as on renal excretion 
(the latter also concerns DHC). On the other hand, the 
analgesic effect and side effects of DHC do not depend 
on the activity of this enzyme. Step II of the WHO anal-
gesic ladder includes the use of low doses of the “strong” 
opioids (morphine to 30 mg, oxycodone to 20 mg orally 
per day) instead of “weak” opioids [11].
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Table 1. Opioids commonly used in the therapy of  patients with cancer pain
Drug Route of 
administration, 
formulation
Initial dosing, remarks Duration 
of drug 
action 
(hours)
 Tramadol Oral: drops 
(40 drops = 100 mg, 
drops with dropper 
1 dose = 5 drops), 
capsules 50 mg
Drops are especially useful during the titration period and in the therapy  
of the breakthrough pain; 5–20 drops (12.5–50 mg), every 4–6 hours;  
in the therapy of the breakthrough pain, usually 10–20 drops depending  
on the dose regularly administered to control the background pain 
4–6
Controlled release 
tablets and capsules 
50, 100, 200 mg
Controlled release tablets or capsules 50–100 mg, every 12 hours 12
Subcutaneous 
and intravenous:
Tramadol hydrochloride 
— ampules 
50 mg/1 ml, 
100 mg/2 ml
Subcutaneous route: usually from 20–50 mg, every 4–6 hours
Intravenous route: usually used on the ward or in the clinic, usually a dose  
of 50–100 mg in a slow infusion
A maximal dose of tramadol equals 400 mg per day; a double (opioid and 
non-opioid) mechanism of analgesia, less frequent constipation compared 
to other opioids; at the beginning of therapy with tramadol a prophylactic 
administration of antiemetic drug (haloperidol or thiethylperazine) is 
recommended; analgesia and side effects (mostly concerning the opioid 
component) depend on the polymorphism of the CYP2D6 enzyme  
4–6
4
Codeine Oral: tablets 20 mg, 
water solution
Maximal dose of codeine is 240 mg per day; codeine is mostly a pro-drug: it is 
partially metabolised to morphine by the CYP2D6 enzyme; analgesia and side 
effects of codeine depend on the polymorphism of the CYP2D6 enzyme
4–6
Dihydro- 
codeine 
Oral: controlled release 
tablets 60 and 90 mg
The initial dose is usually 2 × 60 mg, maximal dose of dihydrocodeine is 
240 mg per day; analgesia and side effects of dihydrocodeine do not depend 
on the polymorphism of the CYP2D6 enzyme
12
Morphine
 
Oral: dividable tablets 
20 mg, water solution
It is mostly dedicated to titrating the dose and to treating the breakthrough 
pain; opioid-naive patients about 2.5–5 mg, every 4–6 hours; patients with  
no effect of “weak” opioids about 5–10 mg, every 4–6 hours; in the therapy 
of the breakthrough pain usually 10–20% of daily morphine dose 
4–6
Controlled release 
tablets 10, 30, 60, 
100, and 200 mg
Opioid-naive patients usually 10 mg, every 12 hours
Patients with no effect of “weak” opioids usually 20–30 mg, every 12 hours
12
Subcutaneous 
and intravenous:
morphine sulphate 
ampules 20 mg/1 ml
Subcutaneous route: usually 2–3 mg, every 4–6 hours in opioid-naive patients, 
usually about 4–6 mg, every 4–6 hours in patients with no effect of “weak” 
opioids 
Intravenous route: usually 1–2 mg, every 4–6 hours in opioid-naive patients, 
usually about 3–5 mg, every 4–6 hours in patients with no effect of “weak” opioids 
If necessary, a drug dose may be increased and repeated every several minutes 
until the pain relief or to the sedation. Usually used on the ward or in an 
outpatient clinic in order to achieve a rapid analgesia
4–6
4
Æ
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Drug Route of 
administration, 
formulation
Initial dosing, remarks Duration 
of drug 
action 
(hours)
Oxycodone Oral: water solution 
1 mg/1 ml (100 ml and 
250 ml)
Dedicated mostly to titrate the dose and to treat the breakthrough pain; 
opioid-naive patients approximately 2.5–5 mg, every 4–6 hours; patient 
with no effect of “weak” opioids approx. 5–10 mg, every 4–6 hours; in the 
therapy of the breakthrough pain usually approx. 10–20% of the daily dose of 
oxycodone
4–6
Oral: controlled release 
tablets 5, 10, 20, 40, 
60, and 80 mg
Opioid-naive patients approximately 5–10 mg, every 12 hours
Patient with no effect of “weak” opioids approx. 10–20 mg every 12 hours
12
Subcutaneous 
and intravenous:
Oxycodone 
hydrochloride ampules 
10 mg/1 ml and 
20 mg/2 ml
Subcutaneous route: usually 2–3 mg, every 4–6 hours in opioid-naive patients, 
mostly approx. 4–6 mg, every 4–6 hours and in patients with no effect of 
“weak” opioids
Intravenous route: usually 1–2 mg, every 4–6 hours in opioid-naive patients, usually 
approx. 3–5 mg, every 4–6 hours in patients with no effect of “weak” opioids
If necessary the dose may be increased and repeated every several minutes 
until the pain relief or to the sedation. Usually used on the ward or in the 
outpatient clinic in order to achieve a quick analgesia 
4–6
4
Fentanyl Transdermal: 
transdermal systems 
(patches) release: 
12, 25, 50, 75, and 
100 mcg/hour
Usually recommended in patients in whom the efficient dose had been 
previously established with use of “strong” opioids administered orally or 
parenterally — the initial dose of fentanyl should be individually defined, 
depending on the previous dose of the opioid; in selected cases, used in 
patients previously treated with “weak” opioids. Less frequently in opioid- 
-naive patients — the initial dose is 12 mcg/hour; strict monitoring of patients 
is mandatory 
72
Transmucosal: 
intranasal, buccal, 
sublingual
Used in the management of the breakthrough pain in opioid-tolerant patients: 
those receiving the therapy of the background pain with at least 60 mg of 
morphine daily by an oral route or an equivalent daily dose of morphine 
administered by other routes or an equivalent daily dose of another opioid. 
Often, if there is no effect of immediate-release formulations of opioids  
(e.g. morphine, oxycodone) administered orally or through any other route; 
an individual titration from the lowest available dose of a particular product 
is always mandatory; no active metabolites, the drug is metabolised by the 
CYP3A4 enzyme
Bupre - 
norphine
Transdermal: 
transdermal systems 
(patches) release 35, 
52.5, and 70 mcg/hour
The initial dose usually equals 17.5 mcg/hour in opioid-naive patients and 
35 mcg/hour in patients if no effect of “weak” opioids; maximal dose is 
140 mcg/hour 
The metabolism of a drug mostly through the conjugation with glucuronic 
acid, it is mostly eliminated through the gastrointestinal tract, and it is 
preferred in the stable neuropathic pain and in elderly patients as well as in 
patients with impaired renal function 
72–96
Oxycodone/ 
/naloxone
Oral: controlled release 
tablets 5 mg/2.5 mg, 
10 mg/5 mg, 20 mg/ 
/10 mg, 40 mg/20 mg
Opioid-naive patients 5 mg/2.5 mg–10 mg/5 mg, every 12 hours
Patients with no effect of "weak" opioids 10 mg/5 mg–20 mg/10 mg, every 12 hours
In the therapy of the breakthrough pain, usually about 10–20% of the daily 
dose of oxycodone
Patients treated with “strong” opioids — a dose established individually with 
use of the equivalent dose conversion factors and titration 
The maximal dose of product is 2-times daily 80 mg/40 mg
12
Tapentdol Oral: controlled 
release tablets 50 mg, 
100 mg, 150 mg, 
200 mg, 250 mg
Opioid-naive patients 50 mg, every 12 hours; patients with no effect of 
“weak” opioids 50–100 mg, every 12 hours
A maximal dose of the drug is 2-times daily 250 mg 
12
Methadone Oral: syrup 1 mg/1 ml Individual dosing; a drug is recommended in second- or third-line therapy if 
when other opioids are ineffective. Methadone should be used by palliative 
medicine specialists or physicians experienced in pain therapy 
Numerous drug interactions. Potential cardiotoxicity and hypoglycaemic effect 
especially with higher doses of the drug
Variable 
8–24
Table 1 cont. Opioids commonly used in the therapy of  patients with cancer pain
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WHO analgesic ladder step III opioids  
(“strong” opioids)
The WHO analgesic ladder step III opioids that have 
no ceiling effect are recommended in the therapy of a se-
vere and very severe pain (NRS 7–10) [12]. Morphine, 
oxycodone, oxycodone/naloxone, fentanyl, buprenor-
phine, tapentadol, and methadone are available on the 
Polish market, while hydromorphone is not available in 
Poland. According to the recommendations of the Euro-
pean Association for Palliative Care (EAPC), morphine, 
oxycodone, and hydromorphone are first-line opioids 
in the therapy of moderate and severe pain intensity in 
caner patients (I, A). In the therapy of a chronic pain it 
is not recommended to use pethidine and pentazocine 
due to the toxic effects of their metabolites. 
Morphine is a standard opioid recommended by the 
WHO and by the European Society of Medical Onco-
logy (ESMO). The analgesic potential of other opioids 
is compared to that of morphine (I, A). Morphine is 
a pure opioid receptor agonist, mostly of type µ. The 
main metabolites are: morprhine-3-glucuronide and 
morphine-6-glucuronide. Morphine is a hydrophilic 
opioid used by choice in the therapy of pain in patients 
with dyspnoea [13]. Moderate liver impairment does 
not significantly influence the metabolism of the drug. 
Patients with impaired renal function require strict 
monitoring, dose reduction, prolongation of the intervals 
between consecutive drug doses, changing the admini-
stration route to parenteral, or rotation to another 
opioid, due to the reduced elimination of the morphine 
metabolites. Constipation may be a significant problem 
during therapy with morphine. 
In the therapy of pain morphine is used by an oral 
route as immediate-release and controlled-release 
formulations as well as parenterally (subcutaneously, 
intravenously) and rarely intrathecally. The equivalent 
dose of a drug administered orally is three-fold higher 
than the parenteral dose due to lower absorption. The 
therapy is most frequently started from low doses, usu-
ally single dose 5 mg (patient previously not treated with 
“weak” opioids) or 10 mg (patients previously receiving 
“weak” opioids) administered every 4–6 hours (imme-
diate-release tablets or less frequently water solution). 
The use of controlled-release morphine tablets is usually 
started from a dose of about 20–40 mg daily, fractionated 
every 12 hours. The type of the morphine formulation, 
its dose, and route of administration should be individu-
ally determined using the rule of dose titration to achieve 
a satisfactory analgesic effect and acceptable (for the 
patient) side effects (titration). During the therapy of 
the background pain with an oral controlled-release 
morphine formulation the therapy of the breakthrough 
pain usually involves immediate-release morphine 
products administered by an oral route. In patients who 
regularly receive a subcutaneous morphine formulation, 
a rescue dose of the drug is usually given in the same way. 
Concomitant use of morphine and benzodiazepines or 
other drugs that have a depressive influence on the CNS 
increase the risk of sedation, hypotony, and respiratory 
depression. Many drugs taken together with morphine, 
including anticholinergic drugs and serotonin receptor 
antagonists, intensify constipation   
Oxycodone is a semisynthetic agonist of the µ and k 
receptors (I, A). The parent compound as well as me-
tabolites are mostly excreted by kidneys. That is why the 
drug should be used carefully in cases of renal impair-
ment. Oxycodone is administered orally or parenterally 
(subcutaneously or intravenously). The equivalent dose 
ratio of morphine and oxycodone is 1.5–2:1 for the 
oral route. In the case of switch from the parenteral 
administration of oxycodone to the oral route, a 1:2 ra-
tio should be applied, which means that the oral dose 
should be two times higher than the parenteral dose. 
Controlled release oxycodone tablets are administered 
every 12 hours. During the therapy of baseline pain with 
controlled-release oxycodone tablets, breakthrough 
pain episodes may be treated with immediate-release 
oxycodone and morphine oral formulations as well as 
rapid onset fentanyl transmucosal products. 
Oxycodone/naloxone is a combination of oxyco-
done with naloxone in the proportion 2:1 in a single 
controlled-release tablet. The efficacy of this formula-
tion in the therapy of chronic pain in cancer patients 
and with other diseases, as well as the concomitant 
improvement or prevention of opioid-induced con-
stipation, have been shown in clinical trials [14]. The 
recommended daily dose of the formulation should 
not exceed 160 mg/80 mg and should be implemented 
gradually by titration. The contraindication for use of 
oxycodone/naloxone are typical as for all opioids. The 
drug should also be avoided in patients with severe liver 
impairment, portal vein circulation disturbances, renal 
failure, allergy, and diarrhea.
Fentanyl is a pure agonist of the opioid µ receptor. Its 
analgesic potential is about 100:1 compared to morphine. 
A significant lipophilicity of the drug is used in transder-
mal therapy. Fentanyl is metabolised by the CYP3A4 en-
zyme in the liver to the inactive norfentanyl and then 
excreted by kidneys in 90% as inactive metabolites. It is 
well tolerated by patients with moderate liver and renal 
insufficiency. The transdermal and intravenous use of 
fentanyl is relatively safe in the case of advanced chronic 
renal disease (grades 4–5) with glomerular filtration rate 
below 30 ml/min. In comparison to morphine, fentanyl 
has a weaker sedative effect, releases low amounts of 
histamine, and more rarely induces constipation.
Fentanyl is administered through transmucosal and 
parenteral routes. Fentanyl patches can be used trans-
dermally, which are changed every 72 hours; however, 
the analgesic effect of the first patch occurs within 
12 hours and a complete analgesic effect is reached after 
2–5 changes of the patches (II, B). Transdermal fentanyl 
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Table 2. Fentanyl products used in the therapy of the episodes of the breakthrough pain
Selected pharmacokinetic parameters Administration route 
Sublingual 
(Vellofent)
Buccal 
(Effentora)
Intranasal 
(Instanyl)
Intranasal 
(PecFent)
Absolute bioavailability (%) 70 65 89 60
Time to maximal serum concentration (minutes) 50–90 47 9–15 15–21
Half-life (hours) 12 22 3–4 15–25
Onset of the analgesic effect (minutes) 5–10 10–15 5–7 5–10
patches are usually recommended in patients previously 
treated with other WHO pain ladder step III opioids and 
less frequently in patients who do not achieve efficient 
analgesia with the use of “weak” opioids. It is rarely 
recommended in opioid-naive patients. If fentanyl is 
administered to “strong” opioid-naïve patients, it is 
recommended to use the lowest therapeutic dose of the 
drug (12 mcg/hour) and to monitor carefully the clinical 
condition of the patients. Patients with elevated body 
temperature should be specially monitored due to the 
possibility of an extended release of the drug. 
Breakthrough pain that occur during the therapy 
with transdermal fentanyl or with other opioids may be 
managed by rapid-onset fentanyl formulations admin-
istered intranasally or tablets delivered via buccal or 
sublingual route (Table 2). The basic rule for correct 
use of transmucosal fentanyl formulations is titration 
from the lowest available dose, which is mandatory at 
the beginning of the therapy of the breakthrough pain 
as well as at the change of the fentanyl product (e.g. 
from buccal formulation into an intranasal product or 
inversely, or of different intranasal products), after the 
change from the previously used, traditional opioids in 
the therapy of the breakthrough pain (e.g. of the short 
acting morphine or oxycodone products) and in cases of 
important changes of dosage of the opioid used to treat 
the background pain, e.g. rotation (switch) of the opioid. 
It should also be stressed that according to the Summary 
of Product Characteristics, the rapid-onset fentanyl for-
mulations can only be recommended in opioid-tolerant 
patients (a daily oral morphine dose equals at least 60 mg 
or an equivalent morphine dose administered through 
a different route or equivalent dose of another opioid, 
used for at least seven days). During the therapy of the 
breakthrough pain with transdermal fentanyl, immedi-
ate-relase morphine may also be administered orally or 
through another route (subcutaneously, intravenously). 
Buprenorphine is a partial agonist of the µ opioid 
receptors and an antagonist of the k opioid receptor. The 
analgesic potency of the buprenorphine is about 75-fold 
higher than that of morphine. At therapeutic doses (up 
to 15 mg per day) buprenorphine acts as a pure agonist 
of the µ opioid receptors and shows no ceiling effect. The 
metabolites of this drug are excreted in 70–80% through 
the gastrointestinal tract and in a small percentage by 
the kidney. Buprenorphine is a safe opioid in patients 
with chronic renal disease and in dialysis patients. It is 
quickly reabsorbed through the buccal mucosa and is 
used in the form of sublingual tablets administered every 
6–8 hours. Due to its lipophilicity, the drug is also used 
as transdermal patches changed every 72–96 hours (II, 
B). The analgesic effect of the first buprenorphine patch 
is observed within about 12 hours. During therapy of 
baseline pain with buprenorphine, brakthrough pain epi-
sodes should be managed with oral immediate-release 
or subcuteneous morphine products or by rapid-onset 
fentanyl formulations. Buprenorphine patches are the 
only “strong” opioids available as an Rp. prescription 
medicine in Poland (all other “strong” opioids are pre-
scribed on special Rpw. receipts).
Tapentadol represents a new group of opioid analge-
sic drugs that have a double mechanism of action: they 
act as agonists of mu opioid receptors and inhibit the 
reuptake of the noradrenaline in the CNS. Due to its 
double mechanism of action, tapentadol is characterised 
by an analgesic effect typical for opioids and for the an-
tidepressants that are inhibitors of the reuptake of the 
noradrenaline. As well as the efficient analgesia, also in 
patients with neuropathic pain, therapy with tapentadol 
is well tolerated due to the (limited in comparison with 
other opioids) side effects related to its interaction with 
the opioid receptors (especially important in the context 
of the negative impact on the gastrointestinal tract) and 
due to a low risk of interactions with other drugs (the 
drug is metabolised outside the cytochrome P-450 sys-
tem) as well as due to its lower addictive potential.
Methadone is a synthetic agonist of the µ and k 
opioid receptors, an antagonist of the NMDA recep-
tors, and it increases the level of monoamines. Its 
analgesic potential compared to oral morphine equals 
about 4–12:1. Compared to morphine, methadone 
induces less intensive constipation, nausea, and vomit-
ing. Methadone may be safely used in chronic renal 
insufficiency and in dialysis patients. Due to its complex 
pharmacokinetics and serious risk of drug interactions 
and of QT interval propongation, and the possibility of 
hypoglicaemia (especially at daily doses over 40 mg), it is 
recommended that the therapy with methadone should 
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be supervised by physician experienced in analgesic 
therapy. The drug is used as an oral syrup (concentration 
1 mg/1 ml) every 8–12 hours, in single doses of 2.5–5 mg. 
It is recommended not to initially exceed the daily dose 
of about 10 mg of drug in patients previously untreated 
with other “strong” opioids. In patients who do not 
achieve a satisfactory analgesia or who experience severe 
side effects during the therapy with other opioids, the 
switch to methadone is suggested. Besides the therapy 
of chronic pain, methadone is also used to treat opioid 
addiction and abstinence syndromes.  
Adverse effects of opioid analgesics
An individual distribution of the opioid receptors 
in each human may result in a different analgesic effect 
of opioids and of different toxicity profile and intensity. 
The most common side effect induced by opioids is 
opioid-induced constipation (OIC) and other symptoms 
of opioid-induced bowel dysfunction (OIBD). The pro-
phylactic use of oral laxatives (osmotic — macrogol or 
lactulose — solo or in combination with irritants — senna 
derivatives or bisacodyl) and in some cases per rectum 
(e.g. glycerine suppositories) is usually necessary from 
the beginning of the therapy. Nausea and vomiting are 
less frequently observed side effects of opioid use — the 
therapy usually includes metoclopramide, haloperidol, 
and thiethylperazine. Other side effects of opioids are: 
sedation, dry mouth, balance dosorders, itch, excessive 
sweating, hallucinations, respiratory depression (occurs 
rarely and usually due to the inappropriate dosing of 
the opioid), urinary tract syndromes (urine retention), 
myoclonic jerks, and very rarely epileptic attack. In the 
case of occurrence of respiratory depression it is recom-
mended that naloxone (1 ampule = 400 µg should be 
diluted in 10 ml of the 0.9% NaCl and then infused by 
40–80 µg = 1–2 ml every 30–60 seconds until resolution 
of the opioid overdose symptoms) should be adminis-
tered by an intravenous route.
In the case of occurrence of opioid side effects four 
therapeutic approaches are used: to decrease the dose 
of the opioid which is systemically administered, symp-
tomatic treatment, change of the route of opioid admin-
istration, and rotation (switch) of opioids. The concept 
of opioid rotation means a change of the currently used 
opioid analgesic to another opioid. A switch of opioids 
enables the elimination of the metabolites, which may 
be important in patients treated with morphine, with 
deterioration of kidney functioning and dehydration. 
Also, if the therapy with one opioid is inefficient, the 
drug should be changed to another opioid. Due to in-
complete cross tolerance, the equivalent doses of opioids 
should be carefully calculated. It is recommended that 
lower doses should be applied rather than the ones 
suggested in the tables of equivalent doses of opioids, 
which have limited usefulness in clinical practice. In 
each case, an individual single and daily opioid dose 
must be calculated for a particular patient and strict 
monitoring of the therapy during the period of the opioid 
dose titration is required. In the majority of patients, 
a switch of opioids improves the analgesic efficacy and 
decreases the intensity of the side effects. The combina-
tion of two step III opioids is currently quite frequent 
in clinical practice (e.g. morphine or oxycodone with 
fentanyl or with buprenorphine). This attitude is based 
on a slightly different binding of different opioids to the 
particular subtypes of opioid receptors and differences 
in physicochemical properties. Nevertheless, there are 
no univocal recommendations due to the small number 
of the clinical trials involving this issue [15].
Supportive drugs and adjuvant analgesics (co-analgesics)
Supportive drugs are recommended at every step 
of the WHO analgesic ladder. They may be divided 
into co-analgesics (adjuvant analgesics), which have an 
analgesic effect or which intensify the analgesic effect 
of analgesic drugs, and drugs that prevent or treat the 
side effects of opioids (laxatives, antiemetics). While 
the choice of analgesic is based mostly on pain inten-
sity, a choice of adjuvant analgesic is mostly based on 
underlying pain pathomechnism. The analgesics are 
tailored to the intensity of pain. The adjuvant analge-
sics are adjusted to the pathomechanism of pain. The 
co-analgesics are especially useful in the therapy of pain 
with neuropathic and bone components (Table 3) [16]. 
Antiepileptic drugs are the most frequently used group of 
drugs (gabapentin and pregabalin), and rarely some older 
products: valproic acid, clonazepam, carbamazepine (I, A). 
Moreover, antidepressant drugs are also frequently 
used — serotonin and noradrenaline reuptake inhibitors 
(venlafaxine, duloxetine), and tricyclic antidepressants 
(amitriptyline, nortriptyline) (I, A). The other groups 
of drugs that are used to treat neuropathic pain involve 
drugs administered locally (lignocaine and capsaicin) 
(II, C) and systemically: NMDA receptor antagonists 
(ketamine ad dextromethorphan) (II, B). In bone pain 
NSAIDs are usually used (II, A) as well as bisphospho-
nates and denosumab and, due to frequent coexistence of 
neuropathic pain, antiepileptic drugs. Glucocorticoster-
oids are used in the therapy of neuropathic pain induced 
by pressure on the nerves, or in therapy of bone pain, 
especially when there are symptoms of involvement of 
the respiratory tract and dyspnoea, in liver tumors and in 
brain metastases. Careful dosing (titration) of adjuvant 
analgesics is recommended, which allows avoiding or 
at least limiting risk of toxicity that may be especially 
prevalent, when combining with opioids [17]. 
Non-pharmacological methods of pain management
In some cancer patients severe pain cannot be 
efficiently managed by pharmacological methods. In 
these patients some non-pharmacological methods 
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Table 3. The analgesic adjuvants commonly used in the therapy of patients with cancer pain
Group of drugs Drug Dosing, remarks Duration 
of drug 
activity 
(hours)
 Anticonvulsants Gabapentin 
 
Pregabalin
Initially 2–3 × 100–200 mg, usually the dose is gradually increased  
up to 900–2400 mg per day, it is not recommended to exceed the daily dose 
of 3600 mg 
Initially 2 × 75 mg, if necessary the dose may be gradually increased, maximal 
dose 2 × 300 mg. The drug is used in the therapy of the generalised anxiety 
8
9–12
Antidepressants Duloxetine 
Venlafaxine 
Amitriptyline 
The initial dose usually equals 1 × 60 mg, if necessary increased to 
1 × 120 mg; the parallel use of CYP1A2 and CYP2D6 inhibitors and of the 
reversible MAO inhibitors is not recommended; may increase blood pressure. 
Cigarette smoking decreases the AUC by 50%
Dosing of 1 × 75 mg, if necessary the dose may be increased to 1 × 150 mg.  
The therapy of neuropatic pain is off label. Metabolites by CYP2D6 to a main active 
metabolite O-desmethylvenlafaxine and by CYP3A4 to N-desmethylvenlafaxine.  
It has cardiotoxic activity when combined with sympathomimetics
Initial dose is 1 × 25 mg, if necessary the dose may be gradually increased 
to 1 × 75 mg. Therapy of the neuropathic pain is off label. Metabolised by 
CYP2D6 to an active metabolite nortriptyline, which is characterised by a long 
and variable (20–100 hours) plasma half-life. It shows a strong antimuscarinic 
and antihistaminic effect as well as many side effects
16–24
12
24
Glucocortico - 
steroids 
Dexamethasone Dosing: usually 4–16 mg daily in 2 doses, the anti-inflammatory effect is used 
in the short-term therapy of bone pain and of pain induced by pressure to the 
nerve, many indications in urgent situations and in supportive therapy, as well 
as anticancer activity in some tumors 
36
are used: radiotherapy, surgery, physiotherapy, and 
psychotherapy. For bone pain, radiotherapy is highly 
efficient. It results in improvement or even in complete 
resolution of pain in 60–80% of treated patients and 
the analgesic effect persists for many months. In some 
patients surgical procedures are applied: orthopaedic 
surgery, surgical immobilisation — stabilisation, verte-
broplasties — in case of the pathologic fractures of the 
vertebral bodies, peripheral nerves and autonomic plexus 
blockades, sympathetic plexus blocks, and intrathecal 
(subarachnoid or epidural) analgesics administration. 
Due to the complex aetiology of pain and the existence 
of total pain, many patients require psychotherapy and 
social and spiritual support. 
Interventional methods of pain management 
Advances in pharmacology, especially the intro-
duction of many opioids and adjuvant analgesics, has 
resulted in a significant decrease of the use of the inter-
ventional methods in recent years (currently estimated 
at 5–10% of patients). A localised, limited pain resistant 
to pharmacotherapy or occurrence of intractable side 
effects of the pharmacotherapy constitutes the main 
indication for the use of interventional methods [18]. 
Neurodestructive procedures may also be used in the 
early phase of the disease (especially the celiac plexus 
block — II, B or the upper hypogastric plexus block — II, 
C) before the occurrence of tumor-induced, significant 
anatomical deformations. The interventional methods 
should not be considered as step IV of the WHO analgesic 
ladder, but they should be performed adequately early, 
when the patient starts to have pain complaints. This 
approach allows significantly limit the need of combi-
nation pharmacotherapy and/or delay the need of its 
implementation. 
Another logical argument for using these methods is 
the possibility of a direct intervention to the area where 
pain is generated. Performed early, in some case only one 
blockade, it may prevent the development of a poten-
tial pain syndrome (phantom pain after amputation of 
a limb/breast, pain after thoracotomy/mastectomy). The 
blockades are especially effective in the pain syndromes 
modulated by the hyperactivation of the sympathetic 
system. Neuropathic pain constitutes a classical example 
of pain that may depend on the sympathetic system. It 
occurs in 5–8% of the general population and in more 
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than 30% of cancer patients. That is why the blockades 
constitute an important element of therapy of this type of 
pain. Another possible use of interventional techniques 
is the injection of the drugs (opioids, clonidine, baclofen, 
and corticosteroids) to the local area of the structures 
involved in the neoplastic process (intraarticular or to the 
epidural space) [19]. In cancer patients a positive effect 
of the continuous epidural (II, C) or subarachnoid (II, B) 
blockade is observed, especially in neuropathic and bone 
pain, and sometimes also in inflammatory pain due to 
the reduction of paraspinal cord oedema.
The blockades are also used as an important diagnos-
tic-prognostic method. A positive but short-lasting effect 
of the blockade may confirm the indication for a neu-
rodestructive procedure. In cancer patients, all potentially 
positive as well as potential side effects of the proposed 
therapeutic method should be carefully considered. Every 
application of the interventional techniques is associated 
with a risk of complications and side effects. Permanent 
impairment of the nerve structures, especially of the 
peripheral nerve, may result in distressing cosequences 
such as paraesthesia, numbness, or motoric deficit. That 
is why the patient must be informed about the potential 
complications and side effects before performing the pro-
cedure. A patient must also sign an informed consent form 
for this procedure. A neurodestructive procedure may be 
proceeded by a diagnostic-therapeutic blockade with use 
of local anaesthetic dugs (LAD). This approach helps to 
define the source of pain and its mechanism, and it also 
‘shows’ the patients the advantages and disadvantages of 
the planned block/thermolysis. We should not forget that 
the LAD has a stronger effect than the neurodestructive 
measure. Moreover, the patient is exposed to the same 
procedure two times. That is why the performance of a di-
agnostic blockade should always be carefully considered. 
The neurodestructive procedures may be done with 
use of the physical, chemical or mechanical factors. The 
physical factors that injure the neural filaments are low 
(cryolysis) and high temperature (thermolysis), and hypo- 
and hyperosmotic solutions. The chemical factors that 
injure the neural filaments involve ethanol, phenol, and 
glycerol. The mechanical factor is a surgical intersection. 
The neurodestructive mechanism of a chemical sub-
stance that has neurolytic activity is based on induction 
of so-called Wallerian degeneration of the nerve fibers, 
which results in disintegration of proteins and lipids 
in the axons as well as in some changes in the myelin 
sheaths. The increased pressure of the fluids inside the 
nerve fiber impairs the blood circulation in the blood 
vessels supplying a given nerve. In a short period of time 
after the destruction of the nerve structures a regenera-
tion process is induced, the duration of which depends 
on the extension of the neurodestruction. Usually 
a nerve fiber is regenerated by 1 mm per day. The drug 
should be injected to the area of the nerve without caus-
ing any damage to the nerve structure.       
Ethyl alcohol is the oldest and the most frequently 
used neurolytic agent. It has a low toxicity. Ethanol 
is used at concentration of 50–100% (usually 65%). 
Alcohol-induced neurolysis is quick and persists for 
about 5–7 months. The factors that limit the use of 
alcohol include its quick diffusion in the tissues, which 
requires the use of high volumes, which in turn impedes 
the achievement of a space-limited neurolytic effect. 
Moreover, during the injection of the alcohol, a patient 
may feel pain or develop alcohol-induced neuritis. The 
irritating effect of alcohol onto the tissues may be mini-
malised by using 65% alcohol in combination with LAD. 
Irrigation of the needle with 1–2 ml of 0.9% NaCl or with 
lignocaine may also be helpful. Incidental administration 
of alcohol into the tissues may induce local neuralgia. 
Phenol solubility in water is very poor. Only a con-
centration of 6–7% can be achieved at room tempera-
ture. However, it dissolves well in glycerol and a higher 
concentration of phenol (10–15%) may be achieved with 
use of this solvent. An advantage of using a solution of 
phenol in glycerol is the slow release of phenol, which 
assures a better neurolytic effect. A high density of 
glycerol is a disadvantage because it is difficult to inject 
this solution through a long, thin needle. The effect of 
phenol administration is biphasic: a local anaesthetic 
effect appears several seconds after the injection and 
abates in several to a dozen hours. A proper neurolytic 
effect develops slowly over a period of two weeks. Phe-
nol has a neurolytic effect in the concentration over 
5%. The total dose should not exceed 600–800 mg. The 
most important disadvantage of phenol is its toxicity. 
Incidentally, intravenously administered phenol may 
cause the patient’s death due to acute renal failure. The 
period of the neurolytic activity of phenol is difficult to 
predict, usually lasts 2–4 months.
Glycerol has an analgesic effect, but in contrast to 
alcohol and phenol it does not totally abolish the sen-
sation of touch. Alcohol- and glycerol-induced touch 
disorders are poorly tolerated by many patients. The 
mechanism of glycerol activity are unclear. It probably 
mostly interacts with the pathological changes, myeli-
nated axial fibres. Another disadvantage of glycerol is 
its high velocity, which impedes the injection.
In clinical practice neurodestructive procedures are 
mostly applied to the sympathetic nerves or plexus, to 
the sensory fibres of the spine, and selectively to mixed 
nerves [20]. The most common uses of blockades and 
blocks in cancer patients are presented in Table 4.    
Summary
Achievement of the optimal analgesic effect in 
cancer patients requires a complex clinical evaluation 
of the pain, with a detailed analysis of its pathomecha-
nism, intensity, and time pattern of pain complains 
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Table 4. The use of blockades and of blocks in cancer patients
Type of pain Blockade/block/thermolysis Commentary 
I. Somatic pain
Muscular-facial Trigger-points blockades, muscles and their fascia 
injections, peripheral nerves blockades (e.g. 
suprascapular nerve, intercostal nerves)
Technically very easy method, safe, worth to try 
and to propagate 
Bone-articular Blockades of the intravertebral and 
interapophyseal joints
Technically difficult procedure, demands experience, 
a blockade may give a long-lasting effect
II. Visceral pain
Induced by cancer Stellate ganglion or (C7-Th3)
Coeliac plexus 
Superior hypogastric plexus 
Lumbar part of the sympathetic trunk 
Technically difficult procedure, demands 
experience, the methods are efficient; however, 
supportive therapy and the monitoring of the 
position of the end of the needle by RTG or USG 
imaging are necessary.
Colicky Epidural blockade of the lumbar section Alternative to systemically administered opioids
Myocardial infarct Blockade of the stellate ganglion, epidural 
blockade of the thoracic section (Th1–Th4)
Good analgesic effect, decreases blood pressure 
in the pulmonary artery  
III. Vascular pain Stellate ganglion or C7-Th3
Lumbar section of the sympathetic trunk 
Effect depends on the clinical stage of the 
disease, highly effective in pain at rest 
IV. Neuropathic pain
A complex regional pain 
syndrome
Stellate ganglion Th2
Lumbar section of the sympathetic trunk 
Segmental intravenous sympathectomy  
A therapy by choice in the early phase
Pancoast syndrome Stellate ganglion
Epidural blockade of the cervical segment
Alternative in case of an ineffective 
pharmacotherapy of neuropathic pain
Neuralgias of the cranial 
nerves
Blockades of the peripheral branches of the 
cranial nerves  
Blockade of the Gasser's ganglion 
Blockade of the pterygopalatine ganglion  
Technically uncomplicated procedure, efficient  
in the early phase of the disease  
Technically difficult procedure, demands the 
monitoring of the position of the end of the 
needle by RTG or USG imaging
Postherpetic neuralgia (PHN) Blockades of the sympathetic system  Efficient during the first 6 months from the onset 
of the disease
Radiculopathies Epidural blockade
Paravertebral blockades with addition of steroid Efficient in the acute phase of the disease
Stump pain Trigger points blockade Technically simple procedures, demand at least 
two stimulations; a therapy by choice in the early 
phase of the disease
Phantom pain Blockades of the sympathetic system Demands the monitoring of the position of the 
end of the needle by RTG or USG imaging
(background and breakthrough-episodic pain). The 
evaluation of pain should also include other symptoms, 
comorbidities, and psychological, social, and spiritual 
dimensions, which may influence patients’ suffering 
and the occurrence of total pain. Local and systemic 
cancer therapy is also important because it may induce 
or increase the pain induced by cancer or by any other 
diseases. Implementation of the recommended therapy, 
which involves the mechanism of pain, time pattern, and 
intensity of pain, increases the efficacy and significantly 
shortens the time necessary to achieve an effective anal-
gesia. It also decreases the intensity and the frequency 
of occurrence of opioid-induced side effects. In cancer 
patients and in different types of chronic pain a standard 
management should be based on the algorithm of the 
WHO analgesic ladder. Individualisation of the pain 
therapy is recommended depending on the patient’s 
clinical situation. The efficient management of other 
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cancer-induced symptoms should also be assured. Pallia-
tive and supportive care significantly improve well-being 
of cancer patients, may prolong overall survival time, 
and positively influence the quality of life of patients 
and their caregivers.
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